KUR Stock Overview
A clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Kura Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.81 |
| 52 Week High | US$21.09 |
| 52 Week Low | US$4.97 |
| Beta | 0.50 |
| 1 Month Change | 5.37% |
| 3 Month Change | -30.86% |
| 1 Year Change | -69.96% |
| 3 Year Change | -46.19% |
| 5 Year Change | -58.78% |
| Change since IPO | -18.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| KUR | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.5% | 1.8% | 2.5% |
| 1Y | -70.0% | -13.8% | 13.4% |
Return vs Industry: KUR underperformed the German Biotechs industry which returned -14.9% over the past year.
Return vs Market: KUR underperformed the German Market which returned 15% over the past year.
Price Volatility
| KUR volatility | |
|---|---|
| KUR Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: KUR has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: KUR's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 192 | Troy Wilson | kuraoncology.com |
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd.
Kura Oncology, Inc. Fundamentals Summary
| KUR fundamental statistics | |
|---|---|
| Market cap | €511.44m |
| Earnings (TTM) | -€159.90m |
| Revenue (TTM) | €59.77m |
7.4x
P/S Ratio-2.8x
P/E RatioIs KUR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KUR income statement (TTM) | |
|---|---|
| Revenue | US$67.99m |
| Cost of Revenue | US$175.05m |
| Gross Profit | -US$107.06m |
| Other Expenses | US$74.83m |
| Earnings | -US$181.89m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.10 |
| Gross Margin | -157.46% |
| Net Profit Margin | -267.52% |
| Debt/Equity Ratio | 2.6% |
How did KUR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/06 21:01 |
| End of Day Share Price | 2025/05/06 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kura Oncology, Inc. is covered by 20 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Jason Zemansky | BofA Global Research |
| Leah Rush Cann | Brookline Capital Markets |